SBT6050, a HER2-Directed TLR8 ImmunoTAC™ therapeutic, is designed to be a systemically administered, potent myeloid cell agonist with tumor-localized activity.

The tumor microenvironment (TME) is replete with myeloid cell populations, including tumor associated macrophages (TAMs), myeloid cell-derived suppressive cells (MDSCs), and conventional dendritic cells (cDCs). When activated or reprogrammed, these cell types orchestrate multiple mechanisms for tumor eradication.

TLR8 is robustly expressed in human myeloid cells prevalent in tumors and not in cell types outside of the myeloid cell lineage, reducing the risk of “off-target” activation. TLR8 is the only innate immune receptor with this profile.

TLR8 activation of myeloid cells produces an anti-tumor innate immune response that includes direct tumor cell killing, recruitment of a diverse array of immune cell subsets, and the reprogramming of immunosuppressive immune cell populations into a productive or pro-inflammatory state.

TLR8 activation of myeloid cells drives a T cell dependent immune response through the enhancement of neoantigen presentation by myeloid cells, recruitment of T cells into the TME, and the production of cytokines that together generate potent, durable anti-tumor immune responses.

SBT6050 drives tumor clearance through an innate immune response, even in the absence of T cells, and activates multiple anti-tumor immune mechanisms.